Sarah R. Senum

Sarah R. Senum

Auto-generated profile, based on publicly available information

Sarah R. Senum

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
EGEmilie Cornec-Le Gall
Emilie Cornec-Le Gall
RORory J. Olson
Rory J. Olson
WBWhitney Besse
Whitney Besse
CHChristina M. Heyer
Christina M. Heyer
VGVladimir G. Gainullin
Vladimir G. Gainullin
PHPeter C. Harris
Peter C. Harris

18 May 2017 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
IIIoan-Andrei Iliuta
Ioan-Andrei Iliuta
VKVinusha Kalatharan
Vinusha Kalatharan
KWKairong Wang
Kairong Wang
EGEmilie Cornec-Le Gall
Emilie Cornec-Le Gall
JCJohn Conklin
John Conklin
PYPei York
Pei York
The absence of a positive family history (PFH) in 10%–25% of patients poses a diagnostic challenge for autosomal dominant polycystic kidney disease (ADPKD). In the Toronto Genetic Epidemiology Study of Polycystic Kidney Disease, 210 affected probands underwent renal function testing, abdominal imaging, and comprehensive PKD1 and PKD2 mutation screening. From this cohort, we reviewed all patients with and without an apparent family history, examined their parental medical records, and performed renal imaging in all available parents of unknown disease status. Subsequent reclassification of 209 analyzed patients revealed 72.2% (151 of 209) with a PFH, 15.3% (32 of 209) with de novo disease, 10.5% (22 of 209) with an indeterminate family history, and 1.9% (four of 209) with PFH in retrospect. Among the patients with de novo cases, we found two families with germline mosaicism and one family with somatic mosaicism. Additionally, analysis of renal imaging revealed that 16.3% (34 of 209) of patients displayed atypical PKD, most of which followed one of three patterns: asymmetric or focal PKD with PFH and an identified PKD1 or PKD2 mutation (15 of 34), asymmetric and de novo PKD with proven or suspected somatic mosaicism (seven of 34), or focal PKD without any identifiable PKD1 or PKD2 mutation (eight of 34). In conclusion, PKD without an apparent family history may be due to de novo disease, missing parental medical records, germline or somatic mosaicism, or mild disease from hypomorphic PKD1 and PKD2 mutations. Furthermore, mutations of a newly identified gene for ADPKD, GANAB, and somatic mosaicism need to be considered in the mutation-negative patients with focal disease.

6 August 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
SLSravanthi Lavu
Sravanthi Lavu
LVLisa E. Vaughan
Lisa E. Vaughan
SSSarah R. Senum
Sarah R. Senum
TKTimothy L. Kline
Timothy L. Kline
ACArlene B. Chapman
Arlene B. Chapman
PHPeter C. Harris
Peter C. Harris
BACKGROUND: A treatment option for autosomal dominant polycystic kidney disease (ADPKD) has highlighted the need to identify rapidly progressive patients. Kidney size/age and genotype have predictive power for renal outcomes, but their relative and additive value, plus associated trajectories of disease progression, are not well defined. METHODS: The value of genotypic and/or kidney imaging data (Mayo Imaging Class; MIC) to predict the time to functional (end-stage kidney disease [ESKD] or decline in estimated glomerular filtration rate [eGFR]) or structural (increase in height-adjusted total kidney volume [htTKV]) outcomes were evaluated in a Mayo Clinic PKD1/PKD2 population, and eGFR and htTKV trajectories from 20–65 years of age were modeled and independently validated in similarly defined CRISP and HALT PKD patients. RESULTS: Both genotypic and imaging groups strongly predicted ESKD and eGFR endpoints, with genotype improving the imaging predictions and vice versa; a multivariate model had strong discriminatory power (C-index = 0.845). However, imaging but not genotypic groups predicted htTKV growth, although more severe genotypic and imaging groups had larger kidneys at a young age. The trajectory of eGFR decline was linear from baseline in the most severe genotypic and imaging groups, but it was curvilinear in milder groups. Imaging class trajectories differentiated htTKV growth rates; severe classes had rapid early growth and large kidneys, but growth later slowed. CONCLUSION: The value of imaging, genotypic, and combined data to identify rapidly progressive patients was demonstrated, and reference values for clinical trials were provided. Our data indicate that differences in kidney growth rates before adulthood significantly define patients with severe disease. FUNDING: NIDDK grants: Mayo DK058816 and DK090728; CRISP DK056943, DK056956, DK056957, and DK056961; and HALT PKD DK062410, DK062408, DK062402, DK082230, DK062411, and DK062401.

19 July 2018 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
MEMarie E. Edwards
Marie E. Edwards
FCFouad T. Chebib
Fouad T. Chebib
MIMaria V. Irazabal
Maria V. Irazabal
TOTroy G. Ofstie
Troy G. Ofstie
LBLisa A. Bungum
Lisa A. Bungum
VTVicente E. Torres
Vicente E. Torres
Background and objectives: In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy. Design, setting, participants, & measurements: One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for ≥1 year (mean±SD, 4.6±2.8; range, 1.1–11.2) were analyzed for efficacy using three approaches: (1) comparison of eGFR slopes and outcome (33% reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; (2) Stability of eGFR slopes with duration of follow-up; and (3) comparison of observed and predicted eGFRs at last follow-up. Results: Patients treated with tolvaptan had lower eGFR slopes from baseline (mean±SD, −2.20±2.18 ml/min per 1.73 m2 per year) and from month 1 (mean±SD, −1.97±2.44 ml/min per 1.73 m2 per year) compared with controls (mean±SD, −3.50±2.09 ml/min per 1.73 m2 per year; P<0.001), and lower risk of a 33% reduction in eGFR (risk ratio, 0.63; 95% confidence interval, 0.38 to 0.98 from baseline; risk ratio, 0.53; 95% confidence interval, 0.31 to 0.85 from month 1). Annualized eGFR slopes of patients treated with tolvaptan did not change during follow-up and differences between observed and predicted eGFRs at last follow-up increased with duration of treatment. Conclusions: Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.

9 October 2019 in Kidney International
Verified
Journal Article
Closed access
KHKatharina Hopp
Katharina Hopp
EGEmilie Cornec-Le Gall
Emilie Cornec-Le Gall
SSSarah R. Senum
Sarah R. Senum
IPIris B.A.W. Te Paske
Iris B.A.W. Te Paske
SRSonam Raj
Sonam Raj
PHPeter C. Harris
Peter C. Harris

12 January 2021 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
AMAmali Mallawaarachchi
Amali Mallawaarachchi
BLBen Lundie
Ben Lundie
YHYvonne Hort
Yvonne Hort
NSNicole Schonrock
Nicole Schonrock
SSSarah R. Senum
Sarah R. Senum
TFTimothy J. Furlong
Timothy J. Furlong